Drug Trial Radar · NCT01844063
Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure
Last checked: Nov 19, 2026Latest source record: Jul 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
210
Planned (sponsor's estimate)
Start
Jul 2013
Primary completion
Jan 2016
Study completion Jan 2019
Sponsor
- Lead sponsor
- Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HBV-related liver failure (HBV-LF), a dramatic clinical syndrome, is characterized with massive necrosis of liver cells. Liver transplantation might be the most effective therapy for HBV-LF. However, there are a lot of problems such as lack of donors, surgical complications, transplant rejection, and high cost, which could limit the application of liver transplantation. It is demonstrated that mesenchymal stem cells could directionally differentiate into hepatocytes and cholangiocytes in injured liver, as well as reduce inflammation of the liver by immune regulation. In this study, we assess the safety and efficacy of human bone marrow and umbilical cord mesenchymal stem cells transplantation for patients with HBV-LF.
Conditions
- Liver Failure
Interventions
Conventional plus BM-MSC treatmentGenetic
Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
Conventional plus UC-MSC treatmentGenetic
Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
Conventional treatmentDrug
Received conventional treatment including: A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival rateTime frame: 72 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qi Zhang
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.